Optibiotix Health CEO Stephen O’Hara commented “High blood pressure and high cholesterol are significant risk factors in cardiovascular disease. Numerous scientific studies have shown that In combination these factors work together to greatly increase the risk of heart disease. LP- LDL, launched by OptiBiotix heath plc, is a product which uniquely reduces both cholesterol and high blood pressure and has the potential to have a greater impact on heart disease than products which target one factor alone”
According to an article in the Times, doctors have expressed alarm regarding the change that would result in four in ten adults being classed as ill, and have warned of a statins-style row concerning the medicalisation of healthy people.
However, a new class of probiotics that modulate the human microbiome may be able to a help people manage their blood pressure more effectively.
OptiBiotix Health, a world leader in developing microbiome modulators, has produced a blood pressure and cholesterol-reducing probiotic called LPLDL.
Human studies have shown that LPLDL is not only a safe natural ingredient, but also that it reduces LDL cholesterol by up to 13.9%, and blood pressure by 5.1%.
LPLDL was found not to cause any side-effects or adverse events. The parallel, double-blind, placebo-controlled, randomised research was done by Glenn Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at the University of Reading.
Stephen O’Hara went on to say: “Although these new proposed blood pressure guidelines have caused some concern from doctors, raising awareness of the dangers of elevated blood pressure is crucial for reducing the levels of cardiovascular disease in the UK.”
“We believe that our microbiome modulating probiotic, LPLDL, is not only a cutting-edge scientific development, but a safe and natural way for people to reduce their blood pressure, and to effectively manage their long-term cardiovascular risk.”
